Eli Lilly and Company

$LLY

NYSEHealthcare

198 stories mentioning Eli Lilly and CompanyUpdated 2d ago

Eli Lilly trades amid a proposed permanent CMS Medicare drug price negotiation framework; an executive sold $2.88 million in shares per an SEC filing.

What are analysts saying about Eli Lilly and Company?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

Rothschild & Co RedburnTarget revisedNeutral33d ago
Price target$915from $900

What's the latest news on Eli Lilly and Company?

Sectors2d ago

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index down 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) easing 0.1%.The iShares Biotechnology ETF (IBB) rose 0.5%.In corporate news, Novo Nordisk (NVO) shares fell 2% after Morgan Stanley downgraded the stock to underweight from equal weight.Eli Lilly (LLY) said Friday that it has completed its acquisition of AtaiBeckley (ATAI), a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions. Lilly shares were down 0.6%.Cosmos Health (COSM) said Friday its unit Cana Laboratories entered a new five-year contract manufacturing deal with Viofar to secure 2.5 million additional units of the Rosartia cardiovascular medicine. Cosmos shares rose 1.2%.Exelixis (EXEL) shares fell 1.5% after it said the US Food and Drug Administration extended the review period for its new drug application for its metastatic colorectal cancer candidate zanzalintinib, in combination with atezolizumab, by three months.

$COSM$EXEL$LLY$NVO

Sectors2d ago

Sector Update: Healthcare Stocks Ease in Afternoon Trading

Healthcare stocks were edging down Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each fractionally lower.The iShares Biotechnology ETF (IBB) rose 0.5%.In corporate news, Eli Lilly (LLY) said Friday that it has completed its acquisition of AtaiBeckley (ATAI), a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions. Lilly shares were slightly lower.Cosmos Health (COSM) said Friday its unit Cana Laboratories entered a new five-year contract manufacturing deal with Viofar to secure 2.5 million additional units of the Rosartia cardiovascular medicine. Cosmos shares gained 5%.Exelixis (EXEL) shares fell 1.7% after it said the US Food and Drug Administration extended the review period for its new drug application for its metastatic colorectal cancer candidate zanzalintinib, in combination with atezolizumab, by three months.

$COSM$EXEL$LLY

US Markets5d ago

Chip, Drug Makers to Drive Non-Residential Construction Rebound, UBS Says

US non-residential construction is approaching a reacceleration, driven by semiconductor and pharmaceutical investments, UBS Securities said in a note emailed Tuesday.The brokerage expects manufacturing-related construction to rebound to more than $200 billion by the end of next year following a 25% drop to $186 billion in the last 12 months.Electric vehicle and battery plants, as well as semiconductor investments, drove the previous buildout cycle from 2021 to 2024, UBS analysts, including Steven Fisher, said."Our analysis and project tracking continues to suggest the drivers this cycle will be another round of semiconductor factories and pharmaceutical projects, in addition to some general industrial and defense related investments," Fisher wrote.UBS upgraded its 2027 growth outlook for non-residential construction to 6.7% from 6%, while lowering the 2026 view to show a 0.9% drop, all in nominal terms.The semiconductor industry has announced nearly $300 billion in year-to-date investments, according to the note. The CHIPS and Science Act, which became law in 2022, initially boosted capacity expansion, but companies have reassessed plans over the last one to two years."For some time, semiconductor manufacturers have remained relatively disciplined in their capacity expansion plans, preferring to add capacity in response to demand rather than build ahead of it," Fisher said. "That demand now appears firmly in place."Pharmaceutical companies have announced about $400 billion in new investments over the last two years, including a commitment of at least $20 billion from Eli Lilly (LLY), amid surging demand for weight loss drugs, the UBS note showed.Defense spending is also on the rise due to the evolving geopolitical situation."In addition to structural drivers discussed above, we think that cyclical drivers will add to growth," Fisher said.The Institute for Supply Management's purchasing managers' index has been expanding for eight months in a row following three years of sluggish performance, according to the brokerage. Separately, S&P Global (SPGI) said last week that manufacturing growth held steady sequentially in August.UBS said equipment rental firm United Rentals (URI) is the main beneficiary of the manufacturing capacity expansion.The brokerage is also positive on United Rentals' peer Equipmentshare.com (EQPT) and construction machinery names Oshkosh (OSK), Caterpillar (CAT), Deere (DE) and CNH Industrial (CNH).Materials providers like Martin Marietta Materials (MLM) and CRH (CRH) and some companies in the engineering and construction sector will also benefit from a pickup in factory activity, according to the note.

$CAT$CNH$CRH$DE$EQPT$LLY$MLM$OSK$SPGI$URI

Wire10d ago

Sector Update: Healthcare Stocks Edge Higher Late Afternoon

Healthcare stocks were slightly higher late Thursday afternoon, with the NYSE Healthcare Index increasing 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.1%.The iShares Biotechnology ETF (IBB) eased 0.3%.In corporate news, Haleon (HLN) has negotiated better shelf placement at Walmart (WMT) and Target (TGT), Reuters reported. The company reportedly said it has offered major retailers better prices and promotions, as well as exclusivity on new products, in exchange for more prominent shelf space. Haleon shares were down 1.1%.Hutchmed (HCM) shares jumped 17% after the company said its unit licensed rights to GSK (GSK) to develop and commercialize experimental cancer treatment HMPL-A830 outside greater China. GSK shares added 0.8%.AbbVie (ABBV) said Thursday that it has completed its acquisition of Apogee Therapeutics (APGE), valuing the clinical-stage biotechnology company at about $10.9 billion, or $135.11 per share. AbbVie shares were down 0.5%.Ultragenyx Pharmaceutical (RARE) shares fell 44% after the firm said a phase 3 study of apazunersen in Angelman syndrome did not achieve the primary endpoint nor a key secondary endpoint.Eli Lilly (LLY) unit Centessa Pharmaceuticals has achieved a late-stage development milestone related to its selective orexin receptor 2 agonist portfolio, triggering an $8.6 million payment to research collaboration partner Nxera Pharma, Nxera said Thursday. Lilly shares were down 0.2%.

$ABBV$HCM$HLN$LLY$RARE

Sectors13d ago

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index decreasing 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.3%.The iShares Biotechnology ETF (IBB) shed 0.4%.In corporate news, Eli Lilly (LLY) has agreed to buy Merida Biosciences for up to $2.875 billion in cash, as it seeks to expand its portfolio of autoimmune and allergic disease therapies, the companies said Monday. Lilly shares were down 1.1%.Takeda Pharmaceutical (TAK), Bayer, CSL, and other mid-size biotech firms are set to announce new pricing deals with the White House on Monday, the Financial Times reported, citing two sources familiar with the matter. The deals will be similar to those finalized by large pharmaceutical companies in which they agreed to lower prices in exchange for tariff relief, according to the report. Takeda shares were down 0.1%.Exelixis (EXEL) said Monday that the US Court of Appeals for the Federal Circuit has affirmed a key portion of the 2024 judgment of the US District Court for the District of Delaware in its favor in the lawsuit Exelixis vs. MSN Laboratories. Exelixis were up 0.4%.Alvotech (ALVO) shares rose past 5% after it said Monday a biologics license application for AVT80 as a proposed interchangeable biosimilar to Entyvio has been accepted for review by the US Food and Drug Administration.

$ALVO$EXEL$LLY$TAK

Asia Markets13d ago

Update: US Equity Indexes Fall While Benchmark Treasury Yield Jumps With Crude Oil as Iran Hostilities Resume

(Updates with index/price moves, macroeconomic data, and company/geopolitical news from the first paragraph.)US equity indexes declined as investors weighed renewed Washington-Tehran military escalation amid higher crude oil prices and a march up in the 10-year government bond yield to the highest in about a month.The Nasdaq Composite fell 0.4% to 26,309.5, the S&P 500 retreated 0.4% to 7,677.6, and the Dow Jones Industrial Average slid 0.7% to 53,208.3 after midday Monday. All sectors, except energy, declined. Communication services led decliners, followed by utilities, industrials, and real estate.Iran and the US traded attacks for the first time in over a month overnight into Monday, CNN reported. Iran said it attacked US bases in Jordan and US military targets at the Al Minhad airbase in the United Arab Emirates after US forces bombed two rocket launchers on Iran's Larak Island, according to a report from Al Jazeera, a Middle Eastern broadcaster.The US military struck the two launchers that a US official said were attempting to deploy mines into the Strait of Hormuz, Reuters reported. The United Arab Emirates condemned the Iranian drone attack on Monday as a "dangerous escalation" and a flagrant violation of its sovereignty, the news report said.President Donald Trump said the US will respond to an Iranian attack on US forces overnight in Jordan, Fox News reported. US air defenses intercepted all but one Iranian missile, which was allowed through because it was not expected to hit anything of consequence, the report said, citing the president.The front-month US West Texas Intermediate crude oil contract advanced 2.7% to $85.62 per barrel, and global benchmark North Sea Brent climbed 4.8% to $90.32 per barrel.In economic news, the Dallas Fed's monthly manufacturing index jumped to 11.6 in August from 1.3 in July, above expectations for 1.6 in a survey compiled by Bloomberg, indicating a faster pace of expansion.Federal Reserve Chair Kevin Warsh's speech Friday was "particularly hawkish, emphasizing that the Fed's 2% inflation target remains the objective but recently, there has been no meaningful movement toward that mark," according to a note from Capital Wealth Planning. Inflation is still above the Fed's target, and Warsh believes that short-term interest rates are the central bank's primary tool to reel it in.The next Fed policy meeting will be in mid-September, with an inflation reading for August to be released beforehand, per the note. Citing the CME's FedWatch tool, the futures market is pricing in one or two rate hikes by the year-end, potentially one in September followed by another in December.US Treasury yields were mixed after midday. The 10-year yield climbed 3.4 basis points to 4.76%, while the two-year was steady at 4.35%. The 30-year yield jumped 4.5 basis points to 5.25%.In company news, Aon (AON) said it has agreed to acquire insurance brokerage USI Insurance Services from KKR (KKR) and other shareholders in an all-cash deal worth roughly $17 billion, as the professional services firm aims to strengthen its presence in the US middle-market insurance segment. Aon shares were down 8%.Eli Lilly (LLY) has agreed to acquire Merida Biosciences for up to $2.875 billion in cash, as it seeks to expand its portfolio of autoimmune and allergic disease therapies, the companies said Monday. Eli Lilly shares were down 1.5%.Tesla (TSLA) is selling a simplified version of Model 3 at a lower price in Hong Kong and Macau than in mainland China, according to media reports and the company's regional websites. Shares jumped 5.2%, the top gainer on the S&P 500 and the Nasdaq.Shares of PG&E (PCG) and Edison International (EIX) were among the decliners, down 18% and 24%, respectively, after the state of California amended legislation to protect wildfire survivors' right to sue utilities for equipment-caused blazes, ABC7 reported Sunday.

Dow JonesNasdaq CompositeS&P 500$AON$EIX$KKR$LLY$PCG$TSLA

Sectors13d ago

Sector Update: Healthcare Stocks Decline Monday Afternoon

Healthcare stocks were lower Monday afternoon, with the NYSE Healthcare Index decreasing 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.4%.The iShares Biotechnology ETF (IBB) shed 0.3%.In corporate news, Eli Lilly (LLY) has agreed to buy Merida Biosciences for up to $2.875 billion in cash, as it seeks to expand its portfolio of autoimmune and allergic disease therapies, the companies said Monday. Lilly shares were down 1.6%.Alvotech (ALVO) shares rose past 4% after it said Monday a biologics license application for AVT80 as a proposed interchangeable biosimilar to Entyvio has been accepted for review by the US Food and Drug Administration.Axsome Therapeutics (AXSM) shares added 0.3% after it said Monday that it has dosed the first patient in its phase 3 trial evaluating AXS-05, its experimental drug intended for smoking cessation.

$ALVO$AXSM$LLY

Sectors13d ago

Sector Update: Healthcare

Healthcare stocks declined Monday afternoon, with the NYSE Healthcare Index decreasing 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.3%.The iShares Biotechnology ETF (IBB) shed 0.3%.In corporate news, Eli Lilly (LLY) has agreed to buy Merida Biosciences for up to $2.875 billion in cash, as it seeks to expand its portfolio of autoimmune and allergic disease therapies, the companies said Monday. Lilly shares were down 1.3%.

$LLY

Wire13d ago

Eli Lilly Strikes $2.88 Billion Deal to Buy Merida Biosciences

Eli Lilly (LLY) has agreed to acquire Merida Biosciences for up to $2.875 billion in cash, as it seeks to expand its portfolio of autoimmune and allergic disease therapies, the companies said Monday.Merida is advancing precision therapeutics for serious autoimmune and allergic diseases, with its lead program -- called MER511 -- currently in early-stage trials for Graves' disease and thyroid eye disease conditions.Graves' disease is an autoimmune disease that affects thyroid gland. Roughly 3 million people in the US get afflicted with the Graves' disease, and about 25% to 40% of these patients go on to develop thyroid eye disease, which could lead to a loss of vision in severe cases, according to the companies.Privately-held Merida is also undertaking preclinical studies for another therapy candidate -- MER769 -- targeting food allergies, asthma, chronic spontaneous urticaria and other allergy-related conditions."We're building our pipeline around therapies that meaningfully change the course of disease, not just its downstream effects," Francisco Ramirez-Valle, senior vice president for Lilly immunology research and early clinical development, said.Lilly could apply Merida's precision approach across a broad range of antibody-driven diseases, according to Ramirez-Valle."Merida was founded to fundamentally change how autoimmune and allergic diseases are treated, by targeting the antibodies driving them directly, rather than suppressing the immune system broadly," Merida Chief Executive Adam Townsend said. "Joining Lilly gives our science the resources and commitment to realize its potential for patients with immune-mediated conditions."The deal, which includes milestone payments and requires regulatory approvals, is anticipated to close in the last quarter of this year, the joint statement said.Shares of Lilly were down down 1.8% in Monday trading. The stock is up 7.4% so far this year.The Merida deal is the latest in a string of acquisitions for Lilly this year. Last month, the pharmaceutical giant announced it agreed to acquire AtaiBeckley (ATAI), a clinical-stage biopharmaceutical company, for up to $3.8 billion.In May, Lilly announced a deal to acquire three vaccine developers with a combined value of up to $3.83 billion, as the drugmaker aimed to strengthen its infectious disease portfolio.Price: $1156.84, Change: $-17.77, Percent Change: -1.51%

$ATAI$LLY

Sectors16d ago

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding about 0.4%.The iShares Biotechnology ETF (IBB) fell 2.7%.In corporate news, BioNTech (BNTX) said it terminated its phase 2 trial evaluating autogene cevumeran as an adjuvant monotherapy in people with colorectal cancer. The trial's independent safety board recommended discontinuing treatment and ending the trial, as further continuation was unlikely to change the efficacy outcome, the company said. Shares fell 8%.Eli Lilly (LLY) said the US Food and Drug Administration approved Mounjaro to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for those events. Lilly shares were down 0.9%.10x Genomics (TXG) said a Delaware federal jury awarded the company more than $4.8 million after finding that three patents held through its Scale Biosciences unit were infringed by Parse Biosciences, a subsidiary of Qiagen (QGEN). 10x Genomics shares were down 5.2%, and Qiagen was shedding 1.3%.Quoin Pharmaceuticals (QNRX) reported "positive" interim data from its ongoing phase 2/3 study of QRX003 in patients with netherton syndrome, and also a private placement financing of up to $50.0 million. Shares surged 18%.

$BNTX$LLY$QGEN$QNRX$TXG

Sectors16d ago

Sector Update: Healthcare Stocks Decline Friday Afternoon

Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding about 0.5%.The iShares Biotechnology ETF (IBB) dropped 2.5%.In corporate news, BioNTech (BNTX) said it terminated its phase 2 trial evaluating autogene cevumeran as an adjuvant monotherapy in people with colorectal cancer. The trial's independent safety board recommended discontinuing treatment and ending the trial, as further continuation was unlikely to change the efficacy outcome, the company said. BioNTech shares fell 7.6%.Eli Lilly (LLY) said the US Food and Drug Administration approved Mounjaro to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for those events. Lilly shares were down 0.8%.Quoin Pharmaceuticals (QNRX) reported interim data from its ongoing phase 2/3 study of QRX003 4% lotion in patients with netherton syndrome and also entered into a securities purchase agreement with new and existing healthcare-focused institutional investors to raise up to about $50 million in gross proceeds. Its shares surged about 29%.

$BNTX$LLY$QNRX

Sectors16d ago

Sector Update: Health Care Stocks Mixed Pre-Bell Friday

Healthcare stocks were mixed premarket Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) gaining by 0.1% and the iShares Biotechnology ETF (IBB) down 0.6%.Cytokinetics (CYTK) shares were down 4%, extending the 1.6% loss in the previous session. The company said Friday that its phase 3 clinical trial of aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy met both primary endpoints.Hutchmed's (HCM) stock was up 1% after the company said a new drug application for fanregratinib to treat liver cancer has been granted conditional approval by China's National Medical Products Administration.Eli Lilly (LLY) stock was up 0.5% after the company said the US Food and Drug Administration approved Mounjaro to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for those events.

$CYTK$HCM$IBB$LLY$XLV

Commodities16d ago

Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Friday Ahead of Warsh Speech

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1% and the actively traded Invesco QQQ Trust (QQQ) was down 0.2% in Friday's premarket activity as markets traded mixed ahead of Fed Chair Kevin Warsh's speech.US stock futures were mixed, with S&P 500 Index futures down 0.03%, Dow Jones Industrial Average futures gaining 0.02%, and Nasdaq futures slipping 0.3% before the start of regular trading.The Chicago PMI for August will be released at 9:45 am ET.Fed Chair Warsh is scheduled to deliver a presentation at the central bank's annual Jackson Hole symposium in Wyoming at 10 am ET.The University of Michigan consumer sentiment report for August is due at 10 am ET.The weekly Baker Hughes domestic oil-and-gas rig count posts at 1 pm ET.In premarket activity, bitcoin was down by 0.4%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 0.5% lower, Ether ETF (EETH) advanced 0.3%, and Bitcoin & Ether Market Cap Weight ETF (BETH) was 3.3% higher.Power Play:FinancialThe State Street Financial Select Sector SPDR ETF (XLF) was flat Direxion Daily Financial Bull 3X Shares (FAS) was down 0.2%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.1% higher.PayPal (PYPL) stock was down more than 14% after Bloomberg News reported that buyout firm Advent and payment-processor Stripe have abandoned their bid to buy the company.Winners and Losers:TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) retreated 0.5%, the iShares US Technology ETF (IYW) was 0.1% lower, and the iShares Expanded Tech Sector ETF (IGM) was up 0.3%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) was down 1.2%, while the iShares Semiconductor ETF (SOXX) declined by 0.9%.Marvell Technology (MRVL) shares were down 7% following the company's fiscal Q2 results.EnergyThe iShares US Energy ETF (IYE) was up 3%, while the State Street Energy Select Sector SPDR ETF (XLE) advanced 0.2%.BW LPG (BWLP) stock was down more than 4% before market open after the company reported lower Q2 revenue.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was up 0.3%, the Vanguard Consumer Staples Index Fund ETF Shares (VDC) gained 0.4%, and the iShares US Consumer Staples ETF (IYK) advanced 0.1%. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) was 0.1% higher. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) increased 0.1%.Toyota Motors (TM) shares were up more than 1% pre-bell after Nikkei Asia reported late Thursday that the company is planning to build an electric Sports Utility Vehicle in China.Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.3%, the Vanguard Health Care Index Fund (VHT) was up 0.03%, while the iShares US Healthcare ETF (IYH) was inactive. The iShares Biotechnology ETF (IBB) was 0.1% lower.Eli Lilly (LLY) stock was up nearly 1% premarket after the company said that the US Food and Drug Administration approved Mounjaro to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for those events.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.4%, while the Vanguard Industrials Index Fund (VIS) was flat and the iShares US Industrials ETF (IYJ) was inactive.Saia (SAIA) stock was up more than 1% before the opening bell after Deutsche Bank raised its price target to $370 from $340.CommoditiesFront-month US West Texas Intermediate crude oil retreated by 0.9% to $82.81 per barrel on the New York Mercantile Exchange. Natural gas was down 2.4% at $2.85 per 1 million British Thermal Units. The United States Oil Fund (USO) fell 1%, while the United States Natural Gas Fund (UNG) was 2.2% lower.Gold futures for November were down by 0.4% at $4,647.30 an ounce on the Comex. Silver futures gained 1.5% to reach $71.29 an ounce. SPDR Gold Shares (GLD) decreased 0.1%, and the iShares Silver Trust (SLV) was 1.7% higher.

Dow JonesNasdaq CompositeS&P 500$BETH$BITO$BWLP$EEM$EETH$EXI$FAS$FAZ$GLD$IBB$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$LLY$MRVL$PMR$PYPL$QQQ$RTH$SAIA$SLV$SOXX$SPY$TM$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD

Wire16d ago

Eli Lilly's Mounjaro Wins FDA Approval to Reduce Cardiovascular Risk in Type 2 Diabetes

Eli Lilly (LLY) said Friday that the US Food and Drug Administration approved Mounjaro to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for those events.The company said the events include cardiovascular death, non-fatal heart attack, or non-fatal stroke.Mounjaro is already approved as an adjunct to diet and exercise to improve blood sugar in adults and children ages 10 and older with type 2 diabetes.The FDA's approval was based on results from the SURPASS-CVOT Phase 3 trial evaluating the efficacy and safety of Mounjaro compared with Eli Lilly's Trulicity in adults with type 2 diabetes and established atherosclerotic cardiovascular disease, the company said.Shares of Eli Lilly were up 1.1% pre-bell.

$LLY

Sectors18d ago

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks fell late Wednesday afternoon, with the NYSE Healthcare Index shedding 1% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.9%.The iShares Biotechnology ETF (IBB) decreased 0.5%.In sector news, the Trump Administration is planning to announce a new round of drug-pricing agreements on Monday with several midsized biotech companies that would offer discounts to state Medicaid programs, Bloomberg reported. The companies would provide discounts so prices align with those charged in foreign markets and would be exempt from Medicare pilot programs requiring similar reductions, while tariff relief is part of some of the discussions, the report said.In corporate news, Eli Lilly (LLY) said Wednesday that a real-world study showed sustained use of its weight-management drug Zepbound was associated with lower healthcare costs among adults older than 55 with overweight or obesity, compared with similar untreated adults. Lilly shares were down 3.3%.Boston Scientific (BSX) is recalling thousands of its percutaneous catheters due to possible arterial sheath tip separation that could lead to complications with a retained tip, the US Food and Drug Administration confirmed in a Wednesday statement. Separately, Boston Scientific has identified a cybersecurity incident that affected some of its IT systems and led to global disruptions in operations, the company said Wednesday in a regulatory filing. Boston Scientific shares fell 3%.Revolution Medicines' (RVMD) Rasonque, or daraxonrasib, has been approved to treat metastatic pancreatic cancer, the US Food and Drug Administration said Wednesday. Revolution shares rose 0.4%.Biuohaven (BHVN) shares surged past 19% in Wednesday trading after the company signed a licensing and collaboration deal with SK Biopharmaceuticals for an investigational focal epilepsy treatment.

$BHVN$BSX$LLY$RVMD

Sectors18d ago

Sector Update: Healthcare

Healthcare stocks declined late Wednesday afternoon, with the NYSE Healthcare Index falling 1% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.9%.The iShares Biotechnology ETF (IBB) decreased 0.5%.In corporate news, Eli Lilly (LLY) said Wednesday that a real-world study showed sustained use of its weight-management drug Zepbound was associated with lower healthcare costs among adults older than 55 with overweight or obesity, compared with similar untreated adults. Lilly shares were down 3.3%.

$LLY

Sectors20d ago

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks decreased late Monday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each fractionally lower.The iShares Biotechnology ETF (IBB) shed 0.4%.In corporate news, Personalis (PSNL) shares fell past 7% after Craig-Hallum downgraded the stock to hold from buy.Biomea Fusion (BMEA) shares surged past 18% after the company said it has completed enrollment in a phase 2 trial of icovamenib in insulin-deficient Type 2 diabetes patients.Eli Lilly (LLY) has launched its Foundayo weight-loss pill in the UK, making Britain the first European country where the oral treatment is available, news outlets reported Monday, citing a company statement. Lilly shares were down 0.5%.Capricor Therapeutics (CAPR) said Monday the US Food and Drug Administration has extended the target action date for its biologics license application for deramiocel as a treatment for Duchenne muscular dystrophy to Nov. 22 from Aug. 22. Capricor shares jumped past 8%.Regenxbio (RGNX) shares fell more than 23% after the company said it does not plan to resubmit the biologics license application for its investigational gene therapy RGX-121 for Hunter syndrome in the near term following a US Food and Drug Administration clinical hold.

$BMEA$CAPR$LLY$PSNL$RGNX

Sectors20d ago

Sector Update: Healthcare Stocks Decline in Afternoon Trading

Healthcare stocks were decreasing Monday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each down 0.1%.The iShares Biotechnology ETF (IBB) shed 0.6%.In corporate news, Eli Lilly (LLY) has launched its Foundayo weight-loss pill in the UK, making Britain the first European country where the oral treatment is available, news outlets reported Monday, citing a company statement. Lilly shares were down 0.8%.Capricor Therapeutics (CAPR) said Monday the US Food and Drug Administration has extended the target action date for its biologics license application for deramiocel as a treatment for Duchenne muscular dystrophy to Nov. 22 from Aug. 22. Capricor shares jumped past 6%.Regenxbio (RGNX) shares fell more than 23% after the company said it does not plan to resubmit the biologics license application for its investigational gene therapy RGX-121 for Hunter syndrome in the near term following a US Food and Drug Administration clinical hold.

$CAPR$LLY$RGNX

Sectors20d ago

Sector Update: Healthcare

Healthcare stocks were softer Monday afternoon, with the NYSE Healthcare Index down 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) fractionally lower.The iShares Biotechnology ETF (IBB) shed 0.7%.In corporate news, Eli Lilly (LLY) has launched its Foundayo weight-loss pill in the UK, making Britain the first European country where the oral treatment is available, news outlets reported Monday, citing a company statement. Lilly shares were down 0.6%.

$LLY

Showing 1-20 of 198